Chinese Japanese Germany Korea
ChemicalBook >> CAS DataBase List >>6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Structure
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- structure
CAS No.
2614417-90-0
Chemical Name:
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-
Synonyms
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)-
CBNumber:
CB012066975
Molecular Formula:
C32H28ClN7O2S
Molecular Weight:
610.13
MDL Number:
MOL File:
2614417-90-0.mol
Last updated:2023-05-25 10:22:58
Request For Quotation

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Properties

Density 1.44±0.1 g/cm3(Predicted)
solubility DMF: 20 mg/ml; DMSO: 10 mg/ml
form A crystalline solid
pka 13.20±0.70(Predicted)

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Chemical Properties,Uses,Production

Description

TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 μM, respectively).1 It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 μM) and for HDAC1 over HDAC2 (IC50 = 2.5 μM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1 phase in HPAC pancreatic cancer cells when used at a concentration of 2 μM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.

References

1. Zhang, X., Zegar, T., Weiser, T., et al. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma Int. J. Cancer 147(10),2847-2861(2020).

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Preparation Products And Raw materials

Raw materials

Preparation Products

6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- Suppliers

Global( 2)Suppliers
Supplier Tel Email Country ProdList Advantage
Shanghai EFE Biological Technology Co., Ltd. 021-65675885 18964387627 info@efebio.com China 9806 58
Supplier Advantage
Shanghai EFE Biological Technology Co., Ltd. 58
6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, N-[4-[[(2-aminophenyl)amino]carbonyl]phenyl]-4-(4-chlorophenyl)-2,3,9-trimethyl-, (6S)- 2614417-90-0 C32H28ClN7O2S